最新ニュース DexCom (NASDAQ:DXCM) 株価情報

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Equities

News

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

DexCom Inc

Throughout the last three months, 11 analysts have evaluated DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, a high estimate of $115.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $93.36.
<img src="https://www.benzinga.com/files/images/story/2025/1737054064_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Financial Insights: DexCom</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 1.97% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.31, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: DexCom Through The Eyes Of 11 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan cut the price target for The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from $186 to $181. JP Morgan analyst Andrea Teixeira maintained an Overweight rating. Procter &amp; Gamble shares closed at $159.65 on Wednesday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<ul>
<li>Canaccord Genuity slashed Concentrix Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NYSE">CNXC</a>) price target from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Concentrix shares closed at $47.47 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from $171 to $151. JP Morgan analyst Ken Goldman maintained a Neutral rating. Hershey shares closed at $155.31 on Wednesday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities increased the price target for Cracker Barrel Old Country Store, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) from $48 to $51. Truist Securities analyst Jake Bartlett maintained a Hold rating. Cracker Barrel shares closed at $57.57 on Wednesday. <a href="https://www.benzinga.com/quote/CBRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) price target from $86 to $104. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. DexCom shares settled at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $94 to $98. Deutsche Bank analyst Brian Bedell maintained a Buy rating. Bank of New York Mellon shares closed at $82.04 on Wednesday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $19 to $9. Citigroup analyst Gustavo Schroden downgraded the stock from Buy to Neutral. StoneCo shares closed at $8.74 on Wednesday.  <a href="https://www.benzinga.com/quote/STNE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from $428 to $437. JP Morgan analyst Matthew Boss maintained an Overweight rating. Lululemon shares settled at $376.66 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Vitesse Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) price target from $28 to $31. Northland Capital Markets analyst Bobby Brooks maintained an Outperform rating. Vitesse Energy shares closed at $27.12 on Wednesday. <a href="https://www.benzinga.com/quote/VTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) price target from $550 to $605. JP Morgan analyst Kian Abouhossein maintained an Overweight rating. Goldman Sachs shares closed at $605.92 on Wednesday. <a href="https://www.benzinga.com/quote/GS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></li>
</ul>

Price Target

Trading Ideas

CBRL

CNXC

LULU

STNE

Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Jeff Johnson upgraded the rating for DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raised the price target from $86 to $104. DexCom shares closed at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Enders upgraded monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from Neutral to Buy but lowered the price target from $302 to $298. Monday.Com shares closed at $234.15 on Wednesday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst David Joyce upgraded the rating for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Neutral to Buy and announced a $955 price target. Netflix shares closed at $848.26 on Wednesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joseph Spak upgraded Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) from Neutral to Buy and raised the price target from $11 to $18. Dana shares closed at $12.07 on Wednesday. <a href="https://www.benzinga.com/quote/DAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Benjamin Nolan upgraded the rating for Canadian National Railway Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) from Hold to Buy but lowered the price target from $132 to $120. Canadian National Railway shares closed at $100.69 on Wednesday. <a href="https://www.benzinga.com/quote/CNI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png" alt="" class="wp-image-736905" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></li>
</ul>

Upgrades

Pre-Market Outlook

MNDY

NFLX

This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

WIIM

DexCom shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $86 to $104.

Baird analyst Jeff Johnson upgrades DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raises the price target from $86 to $104.

Baird Upgrades DexCom to Outperform, Raises Price Target to $104

DexCom shares are trading higher after the company issued Q4 revenue expectations above estimates.

Guidance

DexCom Currently Anticipates FY25 Total Revenue Of $4.60B, Representing Expected Growth Of 14% Over 2024; Est $4.608B

For fiscal 2024, total preliminary, unaudited revenue is approximately $4.032 billion, an increase of 11% over 2023. In conjunction with the preliminary fourth quarter results, the company is also updating 2024 non-GAAP gross profit margin and non-GAAP operating margin guidance to 62% and 19% respectively.&nbsp;
Fourth quarter gross margin is expected to be adversely impacted by a non-cash charge primarily related to inventory damaged in transit and certain build configurations that lowered production yield for the quarter.

DexCom Expects Q4 Total Revenue Of At Least $1.113B, Up 8% YoY (Est $1.097B); Expects Gross Margin To Be Adversely Impacted By Non-cash Charge

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $139,269, and 8 are calls, for a total amount of $460,585.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $95.0 for DexCom over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 2165.5, with a total volume reaching 2,631.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $95.0, throughout the last 30 days.
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736186430_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.7</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$75.00</td>
<td>$109.4K</td>
<td>159</td>
<td align="right">76</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.6</td>
<td>$80.00</td>
<td>$82.1K</td>
<td>10.4K</td>
<td align="right">281</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.9</td>
<td>$2.75</td>
<td>$2.8</td>
<td>$82.00</td>
<td>$77.2K</td>
<td>99</td>
<td align="right">576</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.3</td>
<td>$82.00</td>
<td>$60.0K</td>
<td>99</td>
<td align="right">826</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$1.95</td>
<td>$77.00</td>
<td>$51.8K</td>
<td>19</td>
<td align="right">513</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,506,236, with DXCM's price down by -0.53%, positioned at $80.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $94.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for DexCom, targeting a price of $99. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $91. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for DexCom, targeting a price of $94. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Decoding DexCom's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $120,660, and 5 were calls, valued at $426,440.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $100.0 for DexCom, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 701.83, with a total volume reaching 1,211.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $75.0 to $100.0, throughout the last 30 days.
<h3>DexCom Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735576230_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$135.2K</td>
<td>2.5K</td>
<td align="right">234</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$80.00</td>
<td>$130.0K</td>
<td>2.5K</td>
<td align="right">316</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.95</td>
<td>$2.75</td>
<td>$2.95</td>
<td>$76.00</td>
<td>$59.0K</td>
<td>98</td>
<td align="right">202</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$80.00</td>
<td>$56.2K</td>
<td>790</td>
<td align="right">40</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$75.00</td>
<td>$54.2K</td>
<td>38</td>
<td align="right">67</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 518,458, the DXCM's price is down by -3.01%, now at $77.82. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 38 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $94.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on DexCom, which currently sits at a price target of $91. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on DexCom with a target price of $94. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on DexCom with a target price of $99. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In DXCM Options

<a href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" title="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom">https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom</a>

Biotech

General

Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments

Macro Economic Events

Macro Notification

Market Summary

Economics

TNDM

Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

<ul>
<li>Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform</li>
<li>Dexcom GenAI-enabled technology will leverage Google Cloud's Vertex AI platform and Gemini models and will initially enhance Stelo's Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep</li>
<li>Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health</li>
<li>Dexcom to speak on the future of health AI at CES 2025</li>
</ul>

Dexcom Launched Proprietary Generative AI Platform To Integrate GenAI Into Glucose Biosensing

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 7.58% since its last report. The company recently reported that it has 8.42 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734367523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 3.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into DexCom's Recent Short Interest

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $85 to $91.

Citigroup Maintains Buy on DexCom, Raises Price Target to $91

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and raises the price target from $90 to $94.

Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $94

Watching Shares Of DexCom; Traders Circulating Note American Diabetes Association Updates Standards To Recommend Continuous Glucose Monitoring For Non-Insulin Type 2 Diabetes Patients, Paving Way For Broader Coverage And Market Growth; Bank Of America Reiterates Buy Rating On Dexcom Highlighting Long-Term Earnings Potential

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a high estimate of $120.00, and a low estimate of $85.00. Highlighting a 1.12% decrease, the current average has fallen from the previous average price target of $99.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1733770860_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>A Deep Dive into DexCom's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.97%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): DexCom's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: DexCom's debt-to-equity ratio stands notably higher than the industry average, reaching 1.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From DexCom Analyst Ratings

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $89 to $99.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $99

Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the sa...

Dexcom's Strong Sales Growth and Strategic Advances Support Buy Rating

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Dexcom (DXCM – Research Report) on January 13 and set a price target of $115.00....

Dexcom (DXCM) Gets a Buy from RBC Capital

In a report released today, Jeff Johnson from Robert W. Baird upgraded Dexcom (DXCM – Research Report) to a Buy, with a price target of $104.00. Je...

Dexcom's Growth Potential and Strategic Catalysts Justify Buy Rating and New Price Target

Baird analyst Jeff Johnson upgraded DexCom (DXCM) to Outperform from Neutral with a price target of $104, up from $86. Since DexCom's "surprising" ...

DexCom upgraded to Outperform from Neutral at Baird

Next Century Growth Investors Q4 2024 Commentary

Dexcom (DXCM) Receives a Buy from Piper Sandler

Piper Sandler analyst Matt O'Brien says that last year was a painful one for shares of DexCom (DXCM), and while there are clearly still risks ahead...

Piper bullish on DexCom, says time for investors to come back to the name

Notable gainers among liquid option names this morning include Lam Research (LRCX) $79.36 +3.21, Applied Materials (AMAT) $185.42 +7.04, KLA-Tencor...

Early notable gainers among liquid option names on January 16th

DexCom raised to outperform by Baird

DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback

ADBE

ALHC

AMAT

AMZN

APPF

ATRO

AVAV

AVGO

AVPT

AXON

BWIN

CAVA

CBLL

CDNA

GDYN

GWRE

INOD

KIDS

KLAC

KRUS

LNTH

LRCX

MPTI

MPWR

MYRG

NSSC

NVDA

ODFL

PCTY

PEGA

PNFP

PYCR

RXST

SAIA

SARO

SIBN

SPSC

TMDX

TOST

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Screenshot 2024-12-03 at 7.43.04 PM

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

Health Care

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom

Legal

DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dexcom Reports Third Quarter 2024 Financial Results

Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day

Dexcom and ŌURA Announce Strategic Partnership

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Inari Medical

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Baird

Citigroup

Wells Fargo

Canaccord Genuity

Bernstein

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。
この日、小売トレーダーや投資家の間で注目を集めた売買上位銘柄の状況は下記のようになる。
ウォルト・ディズニー（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>）
ウォルト・ディズニーの株価は0.66％下落し、89.21ドルで終了した。株式の出来高はそれぞれ90.5ドルと89.21ドルで、1年間のレンジは123.74ドルから78.73ドル。この日、ディズニー傘下のスポーツ専門局ESPNが、ABCでの放映を続ける「NBAファイナル」を含むNBAの80試合を11年間にわたって放映すると報じられた。
Eli Lilly and Co（NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>）
Eli Lillyの株価は4.50％下落し、821.19ドルで終了した。株式の最高値と最安値はそれぞれ851.62ドルと806.38ドルで、1年間の範囲は966.1ドルから446.56ドル。この下落は、バイキング・セラピューティクスが肥満治療薬のVK2735の第3相試験に進展したため。
ASTスペースモバイル（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>）
ASTスペースモバイルの株価は24.55％急伸し、16.64ドルで取引を終了。株の一日の取引レンジはそれぞれ16.8ドルと13.6ドルで、1年間の範囲は16.8ドルから1.97ドル。株価上昇の要因は、同社の最初の5つの商用衛星が<a href="https://www.benzinga.com/news/24/07/39958682/ast-spacemobile-stock-is-moving-higher-thursday-whats-going-on">登録完了</a>したことにある。
DexCom（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>）
DexComの株価は3.65％下落し、107.85ドルで終了した。株式の最高値と最安値はそれぞれ112.55ドルと107.56ドルで、1年間の範囲は142ドルから74.75ドル。この下落は、<a href="https://www.benzinga.com/news/earnings/24/07/39971462/dexcom-stock-drops-after-mixed-q2-results-weak-forward-guidance">第2四半期の決算結果の低調さと、弱い先行き見通し</a>が要因となった。
テスラ（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>）
テスラの株価は1.97％上昇し、220.25ドルで終了した。株の一日の取引レンジはそれぞれ226ドルと216.23ドルで、1年間の範囲は278.98ドルから138.8ドル。この日、同社の売上高と業績の不振が原因で<a href="https://www.benzinga.com/24/07/39960058/tesla-faces-a-tough-road-ahead-as-stock-closes-down-12-after-declining-revenue-and-disappointing-ear">株価は急落</a>。
米国株個別ニュース
次の一手:

Comments

DexCom

ニュース

最新ニュース DexCom (NASDAQ:DXCM) 株価情報

金曜日, 7 26, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル